VTGN Quote, Financials, Valuation and Earnings

NovaBay Pharmaceuticals has a net margin of -6020.94% compared to Vistagen Therapeutics's net margin of -49.65%. Vistagen Therapeutics's return on equity of -45.8% beat NovaBay Pharmaceuticals's return on equity of -461.38%.

Vistagen Therapeutics has a consensus price target of $13.00, signalling upside risk potential of 485.59%. On the other hand NovaBay Pharmaceuticals has an analysts' consensus of $0.85 which suggests that it could grow by 46.55%. Given that Vistagen Therapeutics has higher upside potential than NovaBay Pharmaceuticals, analysts believe Vistagen Therapeutics is more attractive than NovaBay Pharmaceuticals.

Vistagen Therapeutics has a beta of 0.562, which suggesting that the stock is 43.775% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals has a beta of 0.897, suggesting its less volatile than the S&P 500 by 10.271%.

Vistagen Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics pays -- of its earnings as a dividend. NovaBay Pharmaceuticals pays out -- of its earnings as a dividend.

Vistagen Therapeutics quarterly revenues are $234K, which are smaller than NovaBay Pharmaceuticals quarterly revenues of $2.4M. Vistagen Therapeutics's net income of -$14.1M is lower than NovaBay Pharmaceuticals's net income of -$1.2M. Notably, Vistagen Therapeutics's price-to-earnings ratio is -- while NovaBay Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics is 94.60x versus 0.16x for NovaBay Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

Ultragenyx Pharmaceutical has a net margin of -6020.94% compared to Vistagen Therapeutics's net margin of -80.9%. Vistagen Therapeutics's return on equity of -45.8% beat Ultragenyx Pharmaceutical's return on equity of -194.36%.

Vistagen Therapeutics has a consensus price target of $13.00, signalling upside risk potential of 485.59%. On the other hand Ultragenyx Pharmaceutical has an analysts' consensus of $91.80 which suggests that it could grow by 141.01%. Given that Vistagen Therapeutics has higher upside potential than Ultragenyx Pharmaceutical, analysts believe Vistagen Therapeutics is more attractive than Ultragenyx Pharmaceutical.

Vistagen Therapeutics has a beta of 0.562, which suggesting that the stock is 43.775% less volatile than S&P 500. In comparison Ultragenyx Pharmaceutical has a beta of 0.607, suggesting its less volatile than the S&P 500 by 39.255%.

Vistagen Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Ultragenyx Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics pays -- of its earnings as a dividend. Ultragenyx Pharmaceutical pays out -- of its earnings as a dividend.

Vistagen Therapeutics quarterly revenues are $234K, which are smaller than Ultragenyx Pharmaceutical quarterly revenues of $164.9M. Vistagen Therapeutics's net income of -$14.1M is higher than Ultragenyx Pharmaceutical's net income of -$133.4M. Notably, Vistagen Therapeutics's price-to-earnings ratio is -- while Ultragenyx Pharmaceutical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics is 94.60x versus 6.15x for Ultragenyx Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

AVITA Medical has a net margin of -6020.94% compared to Vistagen Therapeutics's net margin of -62.96%. Vistagen Therapeutics's return on equity of -45.8% beat AVITA Medical's return on equity of -252.91%.

Vistagen Therapeutics has a consensus price target of $13.00, signalling upside risk potential of 485.59%. On the other hand AVITA Medical has an analysts' consensus of $17.17 which suggests that it could grow by 70.47%. Given that Vistagen Therapeutics has higher upside potential than AVITA Medical, analysts believe Vistagen Therapeutics is more attractive than AVITA Medical.

Vistagen Therapeutics has a beta of 0.562, which suggesting that the stock is 43.775% less volatile than S&P 500. In comparison AVITA Medical has a beta of 1.597, suggesting its more volatile than the S&P 500 by 59.684%.

Vistagen Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. AVITA Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics pays -- of its earnings as a dividend. AVITA Medical pays out -- of its earnings as a dividend.

Vistagen Therapeutics quarterly revenues are $234K, which are smaller than AVITA Medical quarterly revenues of $18.4M. Vistagen Therapeutics's net income of -$14.1M is lower than AVITA Medical's net income of -$11.6M. Notably, Vistagen Therapeutics's price-to-earnings ratio is -- while AVITA Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics is 94.60x versus 4.06x for AVITA Medical. Usually stocks with elevated PS ratios are considered overvalued.

Vanda Pharmaceuticals has a net margin of -6020.94% compared to Vistagen Therapeutics's net margin of -9.24%. Vistagen Therapeutics's return on equity of -45.8% beat Vanda Pharmaceuticals's return on equity of -3.49%.

Vistagen Therapeutics has a consensus price target of $13.00, signalling upside risk potential of 485.59%. On the other hand Vanda Pharmaceuticals has an analysts' consensus of $12.67 which suggests that it could grow by 198.04%. Given that Vistagen Therapeutics has higher upside potential than Vanda Pharmaceuticals, analysts believe Vistagen Therapeutics is more attractive than Vanda Pharmaceuticals.

Vistagen Therapeutics has a beta of 0.562, which suggesting that the stock is 43.775% less volatile than S&P 500. In comparison Vanda Pharmaceuticals has a beta of 0.720, suggesting its less volatile than the S&P 500 by 28.044%.

Vistagen Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Vanda Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Vistagen Therapeutics pays -- of its earnings as a dividend. Vanda Pharmaceuticals pays out -- of its earnings as a dividend.

Vistagen Therapeutics quarterly revenues are $234K, which are smaller than Vanda Pharmaceuticals quarterly revenues of $53.2M. Vistagen Therapeutics's net income of -$14.1M is lower than Vanda Pharmaceuticals's net income of -$4.9M. Notably, Vistagen Therapeutics's price-to-earnings ratio is -- while Vanda Pharmaceuticals's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Vistagen Therapeutics is 94.60x versus 1.24x for Vanda Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.